Figure 2.

Change from baseline to 6 months in A, insulin degludec/liraglutide combination (IDegLira) dose; B, glycated haemoglobin (HbA1c) and C, body weight by baseline therapy subgroup. *P < .0001. Data based on effectiveness analysis set. Significance assessed using a two‐tailed paired t test. BL, baseline; F/U, follow‐up; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; MDI, multiple daily‐dose insulin injections; N, number of patients with data at both time points; OADs, oral antidiabetic drugs